A Phase 1 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 6 sites in 3 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 26th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 13th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
This study's enrollment of 18 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 229th largest by enrollment of the 248 interventional ones that give a count, is one of 14 that started in 2021, is one of 46 in phase 1, and was the 274th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection
Biological: Tezepelumab
Single dose subcutaneous injection
Maximum Observed Serum Concentration (Cmax) of Tezepelumab
Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab
Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab
Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab
Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab
Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/λZ, where λZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Apparent Clearance (CL/F) of Tezepelumab
Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab
Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Apparent Volume of Distribution (Vz/F) of Tezepelumab
Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\*1/ λZ. The PK parameters were estimated using non-compartmental analysis method.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Number of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab
Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.
Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 29 and 85
This Phase I open-label study was conducted in pediatric participants with mild, moderate, or severe asthma at 6 investigational sites in the UK, Hungary, and South Africa between 23 February 2021 and 27 September 2022.
| Milestone | Tezepelumab |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.
| microgram per milliliter (mcg/mL) | Tezepelumab |
|---|---|
| Maximum Observed Serum Concentration (Cmax) of Tezepelumab | 27.1 ± 11.9 |
Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.
| day | Tezepelumab |
|---|---|
| Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab | 3.47 (1.92 to 9.96) |
Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.
| day*mcg/mL | Tezepelumab |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab | 872 ± 285 |
Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.
| day*mcg/mL | Tezepelumab |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab | 974 ± 320 |
Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/λZ, where λZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.
| day | Tezepelumab |
|---|---|
| Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab | 25.7 ± 5.94 |
Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.
| liter per day | Tezepelumab |
|---|---|
| Apparent Clearance (CL/F) of Tezepelumab | 0.0802 ± 0.0295 |
Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.
| liter | Tezepelumab |
|---|---|
| Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab | 3.08 ± 1.32 |
Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\*1/ λZ. The PK parameters were estimated using non-compartmental analysis method.
| liter | Tezepelumab |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Tezepelumab | 2.98 ± 1.26 |
Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.
| Participants | Tezepelumab |
|---|---|
| ADA prevalence | 3 |
| Only baseline ADA positive | 2 |
| Baseline and at least 1 post-baseline ADA positive | 1 |
| Baseline ADA positive regardless of post-baseline | 3 |
| Any post-baseline ADA positive | 1 |
| Treatment-induced ADA positive | 0 |
| Treatment-boosted ADA positive | 0 |
| Treatment-emergent ADA positive | 0 |
Collected over From the first dose administration (Day 1) up to study completion (End of Study/Day 85 visit) or withdrawal date. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| Event | Tezepelumab |
|---|---|
| COVID-19Infections and infestations | 2/18 |
| NasopharyngitisInfections and infestations | 2/18 |
| HeadacheNervous system disorders | 2/18 |
| Viral upper respiratory tract infectionInfections and infestations | 1/18 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/18 |
| VomitingGastrointestinal disorders | 1/18 |
| PyrexiaGeneral disorders | 1/18 |
| Seasonal allergyImmune system disorders | 1/18 |
| ContusionInjury, poisoning and procedural complications | 1/18 |
The Safety analysis set included all participants who received at least 1 dose of tezepelumab.
| Age, Continuous(years) | Tezepelumab |
|---|---|
| Mean | 7.9 ± 1.78 |
| Sex: Female, Male(Participants) | Tezepelumab |
|---|---|
| Female | 7 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab |
|---|---|
| Asian | 2 |
| Black or African American | 1 |
| White | 6 |
| Other | 9 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab |
|---|---|
| Not Hispanic or Latino | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2021 to primary completion in Sep 2022, 19 months.
Results were first posted in Jan 2024, 1 year 3 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 19 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab